Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2014-11-21 17:45:15
Reporting Period:
Filing Date:
Accepted Time:
2014-11-21 17:45:15
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
926617 Vermillion Inc. VRML In Vitro & In Vivo Diagnostic Substances (2835) 330595156
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1162956 T James Lafrance C/o Vermillion, Inc.
12117 Bee Caves Rd Bldg 3 Ste 100
Austin TX 78738
President & Chief Exec Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-11-20 27,907 $1.44 78,022 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
  1. The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.40 to $1.49. The reporting person undertakes to provide to Vermillion, Inc. ("Vermillion"), any security holder of Vermillion or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.